Protective immunity against acute phleboviral infection elicited through immunostimulatory cationic liposome-DNA complexes

Cationic liposome-DNA complexes (CLDC) have been demonstrated to induce potent antitumor activities. The ability of these complexes to elicit protective immunity against viral infections has not been fully explored. Here we report findings on the use of CLDC as an antiviral agent in a mouse model of...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral research 2006-03, Vol.69 (3), p.165-172
Main Authors: Gowen, Brian B., Fairman, Jeff, Smee, Donald F., Wong, Min-Hui, Jung, Kie-Hoon, Pace, Anne M., Heiner, Matthew L., Bailey, Kevin W., Dow, Steven W., Sidwell, Robert W.
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - administration & dosage
Animals
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Biological and medical sciences
Bunyaviridae Infections - immunology
Bunyaviridae Infections - prevention & control
Bunyaviridae Infections - therapy
Bunyaviridae Infections - virology
Cytokines - blood
DNA, Viral - administration & dosage
DNA, Viral - immunology
Female
Injections, Intraperitoneal
Injections, Intravenous
Innate immunity
Liposome
Liposomes - administration & dosage
Liposomes - immunology
Liver - virology
Medical sciences
Mice
Pharmacology. Drug treatments
Phlebovirus
Phlebovirus - immunology
Plasmid DNA
Punta toro virus
Survival Analysis
Viral Load
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cationic liposome-DNA complexes (CLDC) have been demonstrated to induce potent antitumor activities. The ability of these complexes to elicit protective immunity against viral infections has not been fully explored. Here we report findings on the use of CLDC as an antiviral agent in a mouse model of acute phleboviral (Punta Toro virus) disease. CLDC treatment of mice challenged with Punta Toro virus (PTV) resulted in dramatic increases in survival and reduced viral burden and other parameters indicative of protection against disease. CLDC were effective when administered by intraperitoneal and intravenous routes and elicited protective immunity when given within 1 day of virus challenge. Treatments administered 36 h or longer after challenge, however, were not effective in preventing mortality or disease. CLDC treatment induced release of a number of potential antiviral cytokines including IFN-γ, IL-12, and IFN-α. Taken together, our findings indicate that non-specific immunotherapy with CLDC appears to be an effective treatment for blocking PTV-induced disease and suggests that further exploration in other viral disease models may be warranted.
ISSN:0166-3542
1872-9096
DOI:10.1016/j.antiviral.2005.12.002